Alpha-1 MP

Pipeline

Status by Indication[2][1]

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Pulmonary Emphysema in Alpha-1 PI Deficiency1 trial

A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency

Active, not recruiting·Grifols Therapeutics LLC·Phase 3·NCT01983241·345 enrolled

Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency1 trial

An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human), Modified Process 60 mg/kg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin Deficiency

Enrolling by invitation·Grifols Therapeutics LLC·Phase 3·NCT02796937·290 enrolled

Details

Drug Info

Related News